Pooled analysis of factors associated with RP-ILD development in IIM patients: anti-MDA5, anti-Ro-52, anti-Jo-1, anti-TIF1-γ, anti-ARS, and anti-Ku antibodies. This evidence concerns the gene TRIM21 and interstitial lung disease.